Targeting mutant KRAS in lung metastatic colon cancer using RNA technology
Official title: Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA
Funded at Ohio State University · NIH-10979756 · Data updated 2026-11-12
This study is testing a new way to help people with aggressive lung cancer by using tiny particles to deliver treatments that can turn off a harmful gene called KRAS, which helps cancer grow, with the hope of improving their treatment outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 2, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $497,002 |
| NIH project number | 1R01CA293945-01 |
| Project ID | NIH-10979756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung metastatic colon cancer that harbors KRAS mutations.
✕Less likely to help
Patients without KRAS mutations or those with other types of cancer may not receive any benefit from this research.
What this research studies
This research focuses on developing a novel RNA nanotechnology to target and silence the mutant KRAS gene, which is often responsible for aggressive forms of lung metastatic colon cancer. By utilizing exosomes to deliver a combination of gene-silencing agents and therapeutic drugs, the approach aims to improve treatment outcomes for patients with this challenging cancer type. The methodology involves creating a fusion protein that can specifically target and inhibit the expression of the mutant KRAS gene, which is crucial for cancer cell survival and proliferation. Patients may benefit from this innovative strategy that combines gene editing and drug delivery to combat cancer more effectively.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with lung metastatic colon cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using RNA-based technologies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Guo, Peixuan — Ohio State University
- Study coordinator: Guo, Peixuan
Related research
Other NIH-funded projects on the same topics.
-
Colon Cancer Family Registry Cohort study for smarter prevention and care
A large international group is following thousands of people with colorectal cancer and their relatives to better understand risk, causes, and outcomes so future patients can get better guidance and treatment.
-
Bioengineered Networking Microbes for Targeted Colon Cancer Therapy
A project tests a engineered bacteria-based therapy designed to target colon tumors and boost the body’s immune response in people with colon cancer.
-
How DNA methylation patterns are kept in colon cancer and what happens when they’re disrupted
Researchers are studying how the molecular marks that control gene activity are maintained in colon cancer and how breaking these marks affects cancer growth and treatment response.
-
Adaptive aerobic exercise plans during chemotherapy for colon cancer
This study tests personalized aerobic exercise during chemotherapy for people with colon cancer to help them stay on their planned treatment schedule and reduce side effects.
-
Immune regulation in colon cancer and its spread to lymph nodes and liver
A patient-friendly look at how immune system circuits in colorectal cancer and its metastases may influence treatment responses and outcomes.
-
Biomarker discovery in colon cancer with advanced metabolomics
A new project will use advanced chemical analysis to find blood- and tissue-based markers that indicate colon cancer and its progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.